Orexin-Blocking Insomnia Medicines Expand Options

How Do Orexin-Blocking Insomnia Medicines Work?

Orexin is a neuropeptide system that helps maintain wakefulness and alertness. Dual orexin receptor antagonists, commonly called DORAs, block orexin receptors and reduce the drive to remain awake. The US Food and Drug Administration has approved medicines in this class including suvorexant, lemborexant and daridorexant for adults with insomnia characterized by difficulty falling asleep, staying asleep or both.

This mechanism differs from benzodiazepines and so-called Z-drugs, which enhance signaling through gamma-aminobutyric acid pathways. Clinical trials indicate that orexin antagonists can improve measures of sleep onset or maintenance, although benefits vary among patients. They can still cause next-day sleepiness, impaired alertness and unusual sleep-related behavior, so prescribing must account for dose, other sedating substances and the patient's morning responsibilities.

Should Insomnia Medication Replace Cognitive Behavioral Therapy?

Cognitive behavioral therapy for insomnia, or CBT-I, combines sleep scheduling, stimulus control, cognitive techniques and education about behaviors that perpetuate insomnia. The American College of Physicians recommends CBT-I as first-line treatment for adults with chronic insomnia because its benefits can persist after treatment ends and it avoids medication-related adverse effects.

Medication may be considered when CBT-I is unavailable, produces an incomplete response or when symptoms require additional short-term management. The decision should be shared with the patient and accompanied by follow-up for effectiveness, daytime impairment and adverse effects. Digital CBT-I programs may improve access, but persistent insomnia also warrants evaluation for sleep apnea, restless legs syndrome, mood disorders, pain and medicines that disrupt sleep.

Who Needs Extra Caution With Orexin Antagonists?

Orexin antagonists are contraindicated in people with narcolepsy because impaired orexin signaling is central to that disorder. Patients should also discuss alcohol, opioids, sedating antihistamines, anxiety medicines and other sleep medicines with a clinician, as combined central nervous system effects may increase impairment. Product-specific metabolism and drug interactions can also influence the appropriate dose.

Insomnia treatment should be judged by daytime function as well as time spent asleep. A medicine that modestly improves sleep but causes morning impairment may not represent a meaningful clinical benefit. Clinicians should reassess continued need, reinforce behavioral treatment and investigate underlying conditions rather than allowing a sleep prescription to become an automatic long-term refill.